On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
Regeneron Pharmaceuticals received approval from the U.S. Food and Drug Administration for its eye treatment Eylea HD. The approval is for Eylea to treat macular edema following retinal vein occlusion ...
After months of back-and-and forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results